BACKGROUND: A history of multiple primary melanomas (PMs) has been associated with improved survival in patients with early stage melanoma, but whether it also is correlated with survival in patients with metastatic melanoma is unknown. The authors sought to address the latter question in the current study. METHODS: Patients with metastatic melanoma diagnosed at the Melanoma Institute Australia between 1983 and 2008 were identified. Overall survival (OS) was calculated from date of first distant metastasis. Survival analysis was performed using the Kaplan-Meier method, log-rank tests, and multivariate Cox proportional hazards models. RESULTS: Of 2942 patients with metastatic melanoma, 2634 (89.5%) had 1 PM and 308 (10.5%) had >1 PM. Factors that were associated independently with shorter OS were site of metastasis, including the brain (hazard ratio [HR], 2.41; 95% confidence interval [CI], 2.07-2.81; P < .001) and non lung viscera (HR, 1.92; 95% CI, 1.67-2.22; P < .001, vs lymph node/subcutaneous/soft tissue), age >60 years (HR, 1.23; 95% CI, 1.12-1.36; P < .001), shorter disease-free interval from PM to first distant metastasis (≤ 12 months vs >36 months: HR, 1.62; 95% CI, 1.39-1.89; P < .001), and fewer PMs (1 vs >1; HR, 1.26; 95% CI, 1.08-1.47; P = .004). CONCLUSIONS: A history of multiple PM was an independent predictor of improved survival for patients with metastatic melanoma. The results indicate that a history of multiple PMs should be incorporated into multivariate analyses of prognostic factors and treatment outcomes.
BACKGROUND: A history of multiple primary melanomas (PMs) has been associated with improved survival in patients with early stage melanoma, but whether it also is correlated with survival in patients with metastatic melanoma is unknown. The authors sought to address the latter question in the current study. METHODS:Patients with metastatic melanoma diagnosed at the Melanoma Institute Australia between 1983 and 2008 were identified. Overall survival (OS) was calculated from date of first distant metastasis. Survival analysis was performed using the Kaplan-Meier method, log-rank tests, and multivariate Cox proportional hazards models. RESULTS: Of 2942 patients with metastatic melanoma, 2634 (89.5%) had 1 PM and 308 (10.5%) had >1 PM. Factors that were associated independently with shorter OS were site of metastasis, including the brain (hazard ratio [HR], 2.41; 95% confidence interval [CI], 2.07-2.81; P < .001) and non lung viscera (HR, 1.92; 95% CI, 1.67-2.22; P < .001, vs lymph node/subcutaneous/soft tissue), age >60 years (HR, 1.23; 95% CI, 1.12-1.36; P < .001), shorter disease-free interval from PM to first distant metastasis (≤ 12 months vs >36 months: HR, 1.62; 95% CI, 1.39-1.89; P < .001), and fewer PMs (1 vs >1; HR, 1.26; 95% CI, 1.08-1.47; P = .004). CONCLUSIONS: A history of multiple PM was an independent predictor of improved survival for patients with metastatic melanoma. The results indicate that a history of multiple PMs should be incorporated into multivariate analyses of prognostic factors and treatment outcomes.
Authors: James S Wilmott; Andrew J Colebatch; Hojabr Kakavand; Ping Shang; Matteo S Carlino; John F Thompson; Georgina V Long; Richard A Scolyer; Peter Hersey Journal: Mod Pathol Date: 2015-04-03 Impact factor: 7.842
Authors: Robert V Rawson; Peter A Johansson; Nicholas K Hayward; Nicola Waddell; Ann-Marie Patch; Serigne Lo; John V Pearson; John F Thompson; Graham J Mann; Richard A Scolyer; James S Wilmott Journal: Lab Invest Date: 2017-01-09 Impact factor: 5.662
Authors: Anne Kricker; Bruce K Armstrong; Chris Goumas; Nancy E Thomas; Lynn From; Klaus Busam; Peter A Kanetsky; Richard P Gallagher; Loraine D Marrett; Pamela A Groben; Stephen B Gruber; Hoda Anton-Culver; Stefano Rosso; Terence Dwyer; Marianne Berwick Journal: JAMA Dermatol Date: 2013-08 Impact factor: 10.282
Authors: Markus V Heppt; Timo Siepmann; Jutta Engel; Gabriele Schubert-Fritschle; Renate Eckel; Laura Mirlach; Thomas Kirchner; Andreas Jung; Anja Gesierich; Thomas Ruzicka; Michael J Flaig; Carola Berking Journal: BMC Cancer Date: 2017-08-10 Impact factor: 4.430
Authors: Jennifer Keller; Theresa L Schwartz; Jason M Lizalek; Ea-Sle Chang; Ashaki D Patel; Maria Y Hurley; Eddy C Hsueh Journal: Cancer Med Date: 2019-04-05 Impact factor: 4.452
Authors: Thomas E Pennington; Cathy Yunjia Zhao; Andrew J Colebatch; Pablo Fernandez-Peñas; Pascale Guitera; Hazel Burke; Richard A Scolyer; Alexander M Menzies; Matteo S Carlino; Serigne Lo; Georgina V Long; Robyn Pm Saw Journal: Australas J Dermatol Date: 2022-02-21 Impact factor: 2.481
Authors: Kimberley L Kaufman; Swetlana Mactier; Nicola J Armstrong; Duthika Mallawaaratchy; Scott N Byrne; Lauren E Haydu; Valerie Jakrot; John F Thompson; Graham J Mann; Richard A Scolyer; Richard I Christopherson Journal: Clin Exp Metastasis Date: 2014-01-17 Impact factor: 5.150
Authors: M S Carlino; L E Haydu; H Kakavand; A M Menzies; A L Hamilton; B Yu; C C Ng; W A Cooper; J F Thompson; R F Kefford; S A O'Toole; R A Scolyer; G V Long Journal: Br J Cancer Date: 2014-06-10 Impact factor: 7.640